EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis

Belén P Solans, Agathe Béranger, Kendra Radtke, Ali Mohamed, Fuad Mirzayev, Medea Gegia, Nguyen Nhat Linh, Samuel G Schumacher, Payam Nahid, Radojka M Savic

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac973 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Belén P Solans und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering and Therapeutic Sciences, University of California San Francisco Schools of Pharmacy and Medicine, San Francisco, Califo…. Hauptthemen laut MEDLINE: Tuberculosis, HIV Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: World Health Organization, NIGMS NIH HHS, Global Tuberculosis Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Optimal doses of first-line drugs for treatment of drug-susceptible tuberculosis in children and young adolescents remain uncertain. We aimed to determine whether children treated using World Health Organization–recommended or higher doses of first-line drugs achieve successful outcomes and sufficient pharmacokinetic (PK) exposures.

Methods

Titles, abstracts, and full-text articles were screened. We searched PubMed, EMBASE, CENTRAL, and trial registries from 2010 to 2021. We included studies in children aged <18 years being treated for drug-susceptible tuberculosis with rifampicin (RIF), pyrazinamide, isoniazid, and ethambutol. Outcomes were treatment success rates and drug exposures. The protocol for the systematic review was preregistered in PROSPERO (no. CRD42021274222).

Results

Of 304 studies identified, 46 were eligible for full-text review, and 12 and 18 articles were included for the efficacy and PK analyses, respectively. Of 1830 children included in the efficacy analysis, 82% had favorable outcomes (range, 25%–95%). At World Health Organization–recommended doses, exposures to RIF, pyrazinamide, and ethambutol were lower in children than in adults. Children ≤6 years old have 35% lower areas under the concentration-time curve (AUCs) than older children (mean of 14.4 [95% CI 9.9–18.8] vs 22.0 [13.8–30.1] μg·h/mL) and children with human immunodeficiency virus (HIV) had 35% lower RIF AUCs than HIV-negative children (17.3 [11.4–23.2] vs 26.5 [21.3–31.7] μg·h/mL). Heterogeneity and small sample sizes were major limitations.

Conclusions

There is large variability in outcomes, with an average of 82% favorable outcomes. Drug exposures are lower in children than in adults. Younger children and/or those with HIV are underexposed to RIF. Standardization of PK pediatric studies and individual patient data analysis with safety assessment are needed to inform optimal dosing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TuberculosisHIV InfectionsAdultAdolescentChildHumansAntitubercular AgentsPyrazinamideEthambutolRifampinIsoniazidHIV

Stichwörter der Autor:innen

World Health Organization dosingdrug-sensitive tuberculosiseffectivenesspediatricpharmacokinetics

Substanzen

Antitubercular AgentsPyrazinamideEthambutolRifampinIsoniazid

Autor:innen und Institutionen

  • Department of Bioengineering and Therapeutic Sciences, University of California San Francisco Schools of Pharmacy and Medicine, San Francisco, California, USA.
  • UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, California, USA.
  • Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
  • Division of Pulmonary and Critical Care Medicine, School of Medicine, University of California San Francisco, San Francisco, California, USA.

Förderung

  • World Health Organization
  • NIGMS NIH HHS
  • Global Tuberculosis Programme

Zitieren

APA

Solans, B. P., Béranger, A., Radtke, K., Mohamed, A., Mirzayev, F., Gegia, M., Linh, N. N., Schumacher, S. G., Nahid, P., & Savic, R. M. (2023). Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac973

Vancouver

Solans BP, Béranger A, Radtke K, Mohamed A, Mirzayev F, Gegia M, et al. Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac973

BibTeX
@article{Solans2023,
  author = {Solans, Belén P and Béranger, Agathe and Radtke, Kendra and Mohamed, Ali and Mirzayev, Fuad and Gegia, Medea and Linh, Nguyen Nhat and Schumacher, Samuel G and Nahid, Payam and Savic, Radojka M},
  title = {Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac973}
}
Kostenlos starten →